Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332063 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7332053 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8960011 | 0.85 | MTNR1A (0.52) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7275285 | 0.85 | MTNR1A (0.54) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7272029 | 0.85 | MTNR1A (0.54) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7270631 | 0.82 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7270637 | 0.82 | MTNR1A (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL7336826 | 0.82 | DRD2 (0.67) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL2955073 | 0.82 | DRD2 (0.51) | MTNR1AMTNR1BCA1CA2ACHE | |
| Hydrochloric Acid SCHEMBL6844232 | 0.81 | DRD2 (0.65) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
| EP-1280759-A1 | OPTICALLY ACTIVE 2-AMINOTETRALIN DERIVATIVES, THE PROCESSES FOR THE PREPARATION THEREOF AND THE THERAPEUTICAL USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.p.A. (IT) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001085668-A1 | OPTICALLY ACTIVE 2-AMINOTETRALIN DERIVATIVES, THE PROCESSES FOR THE PREPARATION THEREOF AND THE THERAPEUTICAL USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHIESI FARMACEUTICI S.P.A. (IT) | 2001-11-15 | — | — | WO | disclosed |
| EP-0788472-B1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMA SPA (IT) | 2000-08-02 | — | — | EP | disclosed |
| US-6034277-A | Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2000-03-07 | — | — | US | disclosed |
| US-5936125-A | Process for the preparation of 5,6-dihydroxy-2-amino-1,2,3,4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 1999-08-10 | — | — | US | disclosed |
| US-5710336-A | Process for the preparation of 5-6-dihydroxy-2-amino-1, 2, 3, 4-tetrahydronaphthalene derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 1998-01-20 | — | — | US | disclosed |
| EP-0788472-A1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMACEUTICI S.p.A. (IT) | 1997-08-13 | — | — | EP | disclosed |
| WO-1995029147-A1 | A PROCESS FOR THE PREPARATION OF 5,6-DIHYDROXY-2-AMINO-1,2,3,4-TETRAHYDRONAPHTHALENE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | AADAT, AASDHPPT, AAAS | MTNR1A 1642/4885MTNR1B 695/4885CA1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.